Open Orphan has announced that hVIVO has secured a £3m contract with Imperial College to manufacture a SARS-CoV-2 challenge virus, funded by the Welcome Trust. The new challenge virus will be based on new variants of the COVID virus and therefore support future challenge studies to develop and compare vaccines against different forms of the virus.
10 May 2021
Open Orphan* - New COVID Virus Manufacturing Contract
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - New COVID Virus Manufacturing Contract
hVIVO plc (HVO:LON) | 28.8 0 0.5% | Mkt Cap: 195.6m
- Published:
10 May 2021 -
Author:
Andrew Simms -
Pages:
5
Open Orphan has announced that hVIVO has secured a £3m contract with Imperial College to manufacture a SARS-CoV-2 challenge virus, funded by the Welcome Trust. The new challenge virus will be based on new variants of the COVID virus and therefore support future challenge studies to develop and compare vaccines against different forms of the virus.